Camptothecin intermediates are essential compounds used in the synthesis of camptothecin-derived anticancer agents, including irinotecan and topotecan. They are involved in the stepwise assembly or modification of the camptothecin scaffold, which is critical for preserving its biological activity as a topoisomerase I inhibitor. These intermediates provide a reliable foundation for downstream API production, supporting scalable and reproducible synthetic processes. By ensuring structural consistency and process compatibility, they serve as key building blocks in oncology drug development, while enabling flexible adaptation to various synthesis routes.
Camptothecin Intermediates Characteristics
Well-defined chemical structure: Clearly identified molecular structures with standardized characterization ensure consistency across synthesis stages.
API-oriented application: Closvesly linked to downstream APIs, supporting established synthetic routes in oncology drug development.
Reliable quality consistency: Controlled processes ensure reproducibility and stable performance in downstream API manufacturing.
| Name | CAS Number | Molecular Formula | Molecular Weight（g/mol） | Chemical Structure |
| (+)-Camptothecin | 7689-03-4 | C₂₀H₁₆N₂O₄ | 348.35 |  |
| 7-Ethylcamptothecin | 78287-27-1 | C₂₂H₂₀N₂O₄ | 376.41 |  |
| Irinotecan | 97682-44-5 | C₃₃H₃₈N₄O₆ | 586.68 |  |
| Irinotecan hydrochloride | 100286-90-6 | C₃₃H₃₈N₄O₆·HCl | 622.15 |  |
| Topotecan hydrochloride | 123948-87-8 | C₂₃H₂₃N₃O₅ | 421.45 |  |
| Topotecan hydrochloride | 119413-54-6 | C₂₃H₂₃N₃O₅·HCl | 457.91 |  |
| 10-hydroxycamptothecin,HCPT | 19685-09-7 | C₂₀H₁₆N₂O₅ | 364.35 |  |
| 7-Ethylcamptothecin N-oxide | 86639-51-2 | C₂₂H₂₀N₂O₅ | 392.41 |  |
| SODIUM CAMPTOTHECIN | 25387-67-1 | C₂₀H₁₅N₂NaO₄ | 370.34 |  |
| Camptothecin 1-oxide | 86639-48-7 | C₂₀H₁₆N₂O₅ | 364.35 |  |
| 9-NITRO-10-HYDROXYCAMPTOTHECIN | 104267-73-4 | C₂₀H₁₅N₃O₇ | 409.35 |  |
Camptothecin intermediates contribute to the synthesis of camptothecin-derived anticancer agents, whose therapeutic activity is based on the inhibition of DNA topoisomerase I. These drugs stabilize the transient complex formed between topoisomerase I and DNA during replication, preventing the re-ligation of single-strand breaks. As a result, DNA damage accumulates, ultimately leading to apoptosis in rapidly dividing cancer cells. By enabling the precise construction of the camptothecin scaffold, these intermediates play a crucial role in preserving the structural features required for this mechanism of action.
Irinotecan – Colorectal Cancer
A key precursor for irinotecan, used in colorectal cancer therapy, acting by inhibiting DNA topoisomerase I and preventing DNA re-ligation, leading to replication arrest and apoptosis in rapidly dividing tumor cells.
Topotecan – Ovarian & Lung Cancer
Used as a precursor for topotecan, indicated in ovarian and lung cancers, functioning by stabilizing the topoisomerase I–DNA complex, blocking DNA strand rejoining and inducing cytotoxic DNA damage.
Camptothecin Derivatives – Broad Oncology Applications
Serve as key building blocks for various camptothecin derivatives, which act as topoisomerase I inhibitors, trapping enzyme–DNA complexes and disrupting DNA replication, ultimately triggering apoptosis in cancer cells.
B608, #25 Shenbin Rd, Minhang District, Shanghai, China
English
